Characterising lipid lipolysis and its implication in lipid-based formulation development

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 860-871

  Thomas, Nicky ^a   Holm, René ^b   Rades, Thomas ^c   Müllertz, Anette ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

In vitro digestion; In vitro lipolysis models; Lipid based drug delivery systems; Poorly soluble drugs; Self nanoemulsifying drug delivery systems (SNEDDS)

Indexed keywords

ALCOHOL; CINNARIZINE; COLECALCIFEROL; CYCLOSPORIN A; ERGOSTEROL; GLYCEROL OLEATE; HALOFANTRINE; KETOCONAZOLE; OLIVE OIL; PROGESTERONE; SESAME SEED OIL; TRIOCTANOIN; TRIOLEIN;

COLLOID; DIGESTION; DISPERSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; EMULSION; INTESTINE FLUID; LIPID BASED DRUG DELIVERY SYSTEM; LIPOLYSIS; LIPOSOMAL DELIVERY; REVIEW; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; SUSPENSION;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPIDS; LIPOLYSIS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84869114981     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9398-6     Document Type: Review

References (100)

1. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet. 1978;3(5):337-51.
2. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25(1):103-28.
3. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173-82.
4. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21(2):201-30.
5. Hauss DH. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667-76.
6. Anton N, Vandamme T. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res. 2011;28 (5):978-85.
7. Grove M, Nielsen J, Pedersen G, Müllertz A. Bioavailability of seocalcitol (IV): evaluation of lymphatic transport in conscious rats. Pharm Res. 2006;23(11):2681-8.
8. Holm R, Müllertz A, Pedersen GP, Kristensen HG. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm Res. 2001;18(9):1299-304.
9. Khoo S-M, Prankerd RJ, Edwards GA, Porter CJH, Charman WN. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. J Pharm Sci. 2002;91(3):647-59.
10. Lind ML, Jacobsen J, Holm R, Müllertz A. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci. 2008;35(3):211-8.
11. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 2007;96(2):235-48.
12. Tompkins L, Lynch C, Haidar S, Polli J, Wang H. Effects of commonly used excipients on the expression of CYP 3A4 in colon and liver cells. Pharm Res. 2010;27(8):1703-12.
13. Kossena G, Charman W, Wilson C, O'Mahony B, Lindsay B, Hempenstall J, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007;24 (11):2084-96.
14. Branca F, Nikogosian H, Lobstein T, editors. The challenge of obesity in the WHP European region and the strategies for response. Copenhagen, Denmark: WHO; 2007.
15. Carey MC, Small DM, Bliss CM. Lipid digestion and absorption. Annu Rev Physiol. 1983;45(1):651-77.
16. DeNigris SJ, Hamosh M, Kasbekar DK, Lee TC, Hamosh P. Lingual and gastric lipases: species differences in the origin of prepancreatic digestive lipases and in the localization of gastric lipase. Biochim Biophys Acta. 1988;959(1):38-45.
17. Phan CT, Tso P. Intestinal lipid absorption and transport. Front Biosci. 2001;6:d299-319 (1 March 2001).
18. Golding M, Wooster TJ. The influence of emulsion structure and stability on lipid digestion. Curr Opin Colloid Interface Sci. 2010;15(1-2):90-101.
19. Miled N, Canaan S, Dupuis L, Roussel A, Rivière M, Carrière F, et al. Digestive lipases: from three-dimensional structure to physiology. Biochimie. 2000;82(11):973-86.
20. Embleton JK, Pouton CW. Structure and function of gastrointestinal lipases. Advanced Drug Delivery Reviews. 1997;25 (1):15-32.
21. Lowe ME. Structure and function of pancreatic lipase and colipase. Annu Rev Nutr. 1997;17:141-58.
22. Patton JS, Carey MC. Watching fat digestion. Science. 1979;204 (4389):145-8.
23. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(March):231-48.
24. Patton JS, Carey MC. Inhibition of human pancreatic lipase-colipase activity by mixed bile salt-phospholipid micelles. Am J Physiol Gastrointest Liver Physiol. 1981;241(4):G328-36.
25. Erlanson-Albertsson C. Pancreatic colipase. Structural and physiological aspects. Biochim Biophys Acta. 1992;1125(1):1-7.
26. Bezzine S, Ferrato F, Ivanova MG, Lopez V, Verger R, Carrière F. Human pancreatic lipase: colipase dependence and interfacial binding of lid domain mutants. Biochemistry (Mosc). 1999;38 (17):5499-510.
27. Delorme V, Dhouib R, Canaan S, Fotiadu F, Carrière F, Cavalier J-F. Effects of surfactants on lipase structure, activity, and inhibition. Pharm Res. 2011;28(8):1831-42.
28. Larsson A, Erlanson-Albertsson C. The importance of bile salt for the reactivation of pancreatic lipase by colipase. Biochim Biophys Acta. 1983;750(1):171-7.
29. Bloom B, Chaikoff IL, Reinhardt WO. Intestinal lymph as a pathway for transport of absorbed fatty acids of different chain lengths. Am J Physiol Gastrointest Liver Physiol. 1951;166:451-5.
30. Bergström S, Blomstrand R, Borgström B. Route of absorption and distribution of oleic acid and triolein in the rat. Biochem J. 1954;58(4):600-4.
31. Armand M, Borel P, Ythier P, Dutot G, Melin C, Senft M, et al. Effects of droplet size, triacylglycerol composition, and calcium on the hydrolysis of complex emulsions by pancreatic lipase: an in vitro study. J Nutr Biochem. 1992;3(7):333-41.
32. Mansbach CM, Cohen RS, Leff PB. Isolation and properties of the mixed lipid micelles present in intestinal content during fat digestion in man. J Clin Invest. 1975;56(4):781-91.
33. Wickham M, Garrood M, Leney J, Wilson PDG, Fillery-Travis A. Modification of a phospholipid stabilized emulsion interface by bile salt: effect on pancreatic lipase activity. J Lipid Res. 1998;39(3):623-32.
34. Alvarez FJ, Stella VJ. The role of calcium ions and bile salts on the pancreatic lipase-catalyzed hydrolysis of triglyceride emulsions stabilized with lecithin. Pharm Res. 1989;6(6):449-57.
35. Khoo S-M, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998;167 (1-2):155-64.
36. Nielsen FS, Petersen KB, Müllertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur J Pharm Biopharm. 2008;69(2):553-62.
37. Thomas N, Müllertz A, Graf A, Rades T. Influence of lipid composition and drug load on the in vitro performance of selfnanoemulsifying drug delivery systems. J Pharm Sci. 2012;101 (5):1721-31.
38. Hong J-Y, Kim J-K, Song Y-K, Park J-S, Kim C-K. A new selfemulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release. 2006;110(2):332-8.
39. Li XR, Yuan QA, Huang YQ, Zhou YX, Liu Y. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. AAPS PharmSciTech. 2010;11 (2):672-8.
40. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994;11 (2):301-4.
41. Kovarik JM, Mueller EA, Van Bree JB, Tetzloff W, Kutz K. Reduced inter-And intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83(3):444-6.
42. Wandel C, Kim RB, Stein CM. Inactive excipients such as Cremophor® can affect in vivo drug disposition. Clin Pharmacol Ther. 2003;73(5):394-6.
43. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756-61.
44. Kleberg K, Jacobsen J, Müllertz A. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol. 2010;62(11):1656-68.
45. Klein S. The use of biorelevant dissolution media to forecast the in vitro/in vivo performance of a drug. AAPS J. 2010;12(3):397-406.
46. Di Maio S, Carrier RL. Gastrointestinal contents in fasted state and post-lipid ingestion: in vivo measurements and in vitro models for studying oral drug delivery. J Control Release. 2011;151(2):110-22.
47. Kleberg K, Jacobsen F, Fatouros DG, Müllertz A. Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. J Pharm Sci. 2010;99(8):3522-32.
48. Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. A dynamic in vitro lipolysis model: I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci. 2001;14(2):115-22.
49. Jantratid E, Janssen N, Reppas C, Dressman JD. Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update. Pharm Res. 2008;25(7):1663-76.
50. Reymond J-P, Sucker H, Vonderscher J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm Res. 1988;5(10):677-9.
51. Dahan A, Hoffmann A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res. 2006;23 (9):2165-74.
52. Dahan A, Hoffmann A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm. 2007;67(1):96-105.
53. Li Y, McClements DJ. New mathematical model for interpreting pH-stat digestion profiles: Impact of lipid droplet characteristics on in vitro digestibility. J Agric Food Chem. 2010;58(13):8085-92.
54. Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. A dynamic in vitro lipolysis model: II: evaluation of the model. Eur J Pharm Sci. 2001;14(3):237-44.
55. Larsen A, Holm R, Pedersen M, Müllertz A. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil® M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res. 2008;25(12):2769-77.
56. Fatouros DG, Bergenstahl B, Müllertz A. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci. 2007;31(2):85-94.
57. Cuiné JF, Claire L, McEvoy CL, Charman WN, Pouton CW, Edwards GA, Benameur H, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci. 2008;97(2):995-1012.
58. Kaukonen AM, Boyd BJ, Charman WN, Porter CJH. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. Pharm Res. 2004;21(2):254-60.
59. Ali H, Nazzal M, Zaghloul A-AA, Nazzal S. Comparison between lipolysis and compendial dissolution as alternative techniques for the in vitro characterization of a-Tocopherol selfemulsified drug delivery systems (SEDDS). Int J Pharm. 2008;352(1-2):104-14.
60. Han SF, Yao TT, Zhang XX, Gan L, Zhu C, Yu H-Z, et al. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Int J Pharm. 2009;379:18-24.
61. Borgström B. Influence of bile salt, pH, and time on the action of pancreatic lipase: physiological implications. J Lipid Res. 1964;5 (4):522-31. 1964 October 1.
62. Lombardo D, Guy O. Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. II. Action on cholesterol esters and lipid-soluble vitamin esters. BBA Enzym. 1980;611(1):147-55.
63. Larsen AT, Sassene P, Müllertz A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int J Pharm. 2011;417(1-2):245-55.
64. FDA. Guidance for Industry: waiver of in vivo bioavailabilty and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutical classification system. Rockville, MD, USA: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2000 [cited 2012 15.05.]. Available from: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM070246.pdf.
65. Porter CJH, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 2001;50(Supplement 1):S127-47.
66. Staggers JE, Hernell O, Stafford RJ, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry (Mosc). 1990;29(8):2028-40.
67. Fernandez S, Jannin V, Rodier JD, Ritter N, Mahler B, Carrière F. Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol®, medium chain glycerides and PEG esters. BBA Mol Cell Biol Lipids. 2007;1771(5):633-40.
68. MacGregor KJ, Embletona JK, Lacy JE, Perry EA, Solomon LJ, Seager H, et al. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliv Rev. 1997;25(1):33-46.
69. Sek L, Pouton CW, Charman WN. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J Pharm Biomed Anal. 2001;25(3-4):651-61.
70. Fatouros DG, Müllertz A. In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability. Expert Opin Drug Metab Toxicol. 2008;4(1):65-76.
71. Stillhart C, Kuentz M. Comparison of high-resolution ultrasonic resonator technology and Raman spectroscopy as novel process analytical tools for drug quantification in self-emulsifying drug delivery systems. J Pharm Biomed Anal. 2012;59:29-37.
72. Kaukonen AM, Boyd BJ, Porter CJH, Charman WN. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res. 2004;21(2):245-53.
73. Christensen J, Schultz K, Mollgard B, Kristensen HG, Müllertz A. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium-And long-chain triacylglycerols. Eur J Pharm Sci. 2004;23(3):287-96.
74. Söderlind E, Karlsson E, Carlsson A, Kong R, Lenz A, Lindborg S, et al. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol Pharm. 2010;7(5):1498-507. 2010/10/04.
75. Zughaid H, Forbes B, Martin GP, Patel N. Bile salt composition is secondary to bile salt concentration in determining hydrocortisone and progesterone solubility in intestinal mimetic fluids. Int J Pharm. 2012;422(1-2):295-301.
76. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004;21 (8):1405-12.
77. Fatouros DG, Nielsen FS, Douroumis D, Hadjileontiadis LJ, Müllertz A. In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neurofuzzy networks. Eur J Pharm Biopharm. 2008;69(3):887-98.
78. Ross CAC. Fat absorption studies in the diagnosis and treatment of pancreatic fibrosis. Arch Dis Child. 1955;30(152):316-21.
79. Abrams CK, Hamosh M, Hubbard VS, Dutta SK, Hamosh P. Lingual lipase in cystic fibrosis-quantitation of enzyme activity in the upper small intestine of patients with exocrine pancreatic insufficiency. J Clin Invest. 1984;73(2):374-82.
80. Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsionbased drug delivery systems on intestinal permeability and drug release kinetics. J Control Release. 2010;142(1):22-30.
81. Sha X, Yan G, Wu Y, Li J, Fang X. Effect of self-microemulsifying drug delivery systems containing Labrasol® on tight junctions in Caco-2 cells. Eur J Pharm Sci. 2005;24(5):477-86.
82. Fatouros DG, Deen GR, Arleth L, Bergenstahl B, Nielsen FS, Pedersen JS, et al. Structural development of self nanoemulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-Angle X-ray scattering. Pharm Res. 2007;24(10):1844-53.
83. Fatouros DG, Walrand I, Bergenstahl B, Müllertz A. Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products. Pharm Res. 2008;26(2):361-74.
84. Kossena GA, Charman WN, Boyd BJ, Dunstan DE, Porter CJH. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. J Pharm Sci. 2004;92(2):332-48.
85. Kossena GA, Charman WN, Boyd BJ, Porter CJH. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. J Pharm Sci. 2005;94(3):481-92.
86. Sek L, Pouton CW, Kaukonen AM, Charman WN. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol. 2002;54(1):29-41.
87. Rübe A, Klein S, Mäder K. Monitoring of in vitro fat digestion by electron paramagnetic resonance spectroscopy. Pharm Res. 2006;23(9):2024-9.
88. Day JPR, Rago G, Domke KF, Velikov KP, Bonn M. Labelfree imaging of lipophilic bioactive molecules during lipid digestion by multiplex coherent anti-Stokes Raman scattering microspectroscopy. J Am Chem Soc. 2010;132(24):8433-9. 2010/06/23.
89. Warren DB, Anby MU, Hawley A, Boyd BJ. Real time evolution of liquid crystalline nanostructure during the digestion of formulation lipids using synchrotron small-Angle X-ray scattering. Langmuir. 2011;27(15):9528-34.
90. Nielsen FS, Gibault E, Ljusberg-Wahren H, Arleth L, Pedersen JS, Müllertz A. Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. J Pharm Sci. 2007;96 (4):876-92.
91. Dong Y-D, Boyd BJ. Applications of X-ray scattering in pharmaceutical science. Int J Pharm. 2011;417(1-2):101-11.
92. Roshan Deen G, Aagaard AE, Pedersen JS, Fatouros D, Müllertz A, Experimental set-up with flow-Through cell for SAXS studies of in-situ degradation of drug formulations under gastro-intestinal mimicking conditions. 13th International Conference on Small-Angle Scattering; 2006; Kyoto, Japan.
93. Williams HD, Sassene P, Kleberg K, Bakala-N'Goma J-C, Calderone M, Jannin V, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci. 2012. doi:10.1002/jps.23205 (online first).
94. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, et al. Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. J Pharm Sci. 2010;99(12):4982-91.
95. Thomas N, Holm R, Müllertz A, Rades T. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012;160(1):25-32.
96. Psachoulias D, Vertzoni M, Goumas K, Kalioras V, Beato S, Butler J, et al. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res. 2011;28(12):3145-58.
97. Boyd BJ, Porter CJH, Charman WN. Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products. J Pharm Sci. 2003;92(6):1262-71.
98. Lurie DJ, Mäder K. Monitoring drug delivery processes by EPR and related techniques-principles and applications. Adv Drug Deliv Rev. 2005;57(8):1171-90.
99. Schie IW, Wu J, Weeks T, Zern MA, Rutledge JC, Huser T. Label-free imaging and analysis of the effects of lipolysis products on primary hepatocytes. J Biophotonics. 2011;4 (6):425-34.
100. Day JPR, Domke KF, Rago G, Kano H, Hamaguchi H-O, Vartiainen EM, et al. Quantitative coherent anti-Stokes Raman scattering (CARS) microscopy. J Phys Chem B. 2011;115 (24):7713-25. 2011/06/23.